MGN-3
This article was originally published in The Tan Sheet
Executive Summary
Lane Labs supplement has "direct effect" on "tumor cell growth and cytokine production," in addition to previous findings showing agent enhances natural killer cell activity, according to a poster presented by Mamdooh Ghoneum, PhD, Charles Drew University and UCLA, et al., at American Association for Cancer Research annual meeting in New Orleans March 24-28. Lane Lab's Internet promotions for MGN-3, "a patented, Japanese compound consisting of hydrolyzed rice bran extracts modified by Shiitake mushroom enzymes," caused FDA and FTC to charge product is an unapproved drug. While FTC charges have been settled, FDA negotiations are ongoing, Lane Labs notes
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning